Haem iron intake and risk of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort by Ward, Heather A. et al.
European Journal of Clinical Nutrition (2019) 73:1122–1132
https://doi.org/10.1038/s41430-018-0271-2
ARTICLE
Epidemiology
Haem iron intake and risk of lung cancer in the European
Prospective Investigation into Cancer and Nutrition (EPIC) cohort
Heather A. Ward1 et al
Received: 24 April 2018 / Revised: 30 May 2018 / Accepted: 10 June 2018 / Published online: 18 October 2018
© Springer Nature Limited 2018
Abstract
Background Epidemiological studies suggest that haem iron, which is found predominantly in red meat and increases
endogenous formation of carcinogenic N-nitroso compounds, may be positively associated with lung cancer. The objective
was to examine the relationship between haem iron intake and lung cancer risk using detailed smoking history data and
serum cotinine to control for potential confounding.
Methods In the European Prospective Investigation into Cancer and Nutrition (EPIC), 416,746 individuals from 10
countries completed demographic and dietary questionnaires at recruitment. Cox proportional hazards models were used to
estimate hazard ratios (HRs) and 95% conﬁdence intervals (CIs) for incident lung cancer (n= 3731) risk relative to haem
iron, non-haem iron, and total dietary iron intake. A corresponding analysis was conducted among a nested subset of 800
lung cancer cases and 1489 matched controls for whom serum cotinine was available.
Results Haem iron was associated with lung cancer risk, including after adjustment for details of smoking history (time since
quitting, number of cigarettes per day): as a continuous variable (HR per 0.3 mg/1000 kcal 1.03, 95% CI 1.00–1.07), and in
the highest versus lowest quintile (HR 1.16, 95% CI 1.02–1.32; trend across quintiles: P= 0.035). In contrast, non-haem
iron intake was related inversely with lung cancer risk; however, this association attenuated after adjustment for smoking
history. Additional adjustment for serum cotinine did not considerably alter the associations detected in the nested
case–control subset.
Conclusions Greater haem iron intake may be modestly associated with lung cancer risk.
Introduction
Lung cancer is the most common cancer in the world, both
in terms of incidence (an estimated 1.8 million cases in
2012) and mortality (1.6 million deaths in 2012), due to the
high case fatality [1]. Smoking is the major determinant of
lung cancer, estimated to be responsible for 85% of all cases
[2], and accordingly is the primary target for public health
interventions to reduce lung cancer incidence. However,
diet is also a potentially modiﬁable risk factor for lung
cancer [3]. Red meat is one such dietary component of
interest: individuals with the highest red meat consumption
were at 34% greater risk of lung cancer compared to the
lowest consumers in a meta-analysis of 18 cohort studies
[4]. One of the proposed mechanisms for the carcinogeni-
city of red meat is haem iron, a subtype of dietary iron that
is found in animal products (primarily red meat). Other
dietary sources of iron include non-haem iron, present
mainly in cereals, legumes, and some vegetables [5]. Con-
sumption of haem iron through diet appears to lead to the
formation of endogenous N-nitroso compounds (NOCs) [6],
which may increase the risk of some common cancers [7].
For lung cancer speciﬁcally, there is evidence from mole-
cular biological studies that haem availability is sig-
niﬁcantly increased in cancer cells and tumours, resulting in
elevated production of haemoproteins and support for can-
cer cell progression through intensiﬁed oxygen consump-
tion and cellular energy production [8].
To date, studies of haem iron in relation to lung cancer
risk are limited to four cohort studies [9–12] and one
case–control study [13]. A 2014 meta-analysis of three of
the prospective studies [9, 11, 12] reported a pooled relative
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risk of 1.12 (95% conﬁdence interval [CI] 0.98–1.29) per
1 mg/day difference in haem iron [7]. The pooled studies
were large cohorts from the United States with similar
dietary assessment methods; however, the studies varied in
haem calculation methods (use of a measured values data-
base [11, 12] versus applying a single value for red and
white meat products [9]) and in approaches to address
smoking as a potential confounder. The magnitude of the
association between smoking and lung cancer, along with
established dietary variability by smoking status (e.g. cur-
rent smokers tend to report lower fruit and vegetable intake
and higher meat intake than non-smokers [14–16]), requires
extensive efforts to control for potential confounding by
smoking in diet–lung cancer analyses. Ideally, such asso-
ciations can be examined separately among never smokers
to reduce the likelihood of smoking as a source of con-
founding. However, to date only the National Institutes of
Health-American Association for Retired Persons Diet and
Health study (NIH-AARP) has been large enough to do
such an analysis, reporting similar positive effect sizes
among smokers and non-smokers [11]. More recently, a
smaller (n= 211 cases) European cohort study reported an
inverse association between haem and lung cancer risk, but
this association was dependent upon adjustment for red
meat in the model and could not be examined separately by
smoking status [10]. In light of these unclear associations,
we sought to further examine the relationship between haem
intake and lung cancer risk in a large European cohort,
using detailed smoking history data and serum cotinine as a
biomarker for tobacco exposure to control for confounding
by smoking status.
Subjects and Methods
Study population
The European Prospective Investigation into Cancer and
Nutrition (EPIC) is a multi-centre prospective cohort to
study the relationship between lifestyle, nutrition and can-
cer. Over 520,000 participants were recruited from 23
centres in 10 European countries between 1992 and 2000:
Denmark (Aarhus and Copenhagen), France, Germany
(Heidelberg and Potsdam), Greece, Italy (Florence, Naples,
Ragusa, Turin and Varese), the Netherlands (Bilthoven and
Utrecht), Norway, Spain (Asturias, Granada, Murcia,
Navarra and San Sebastian), Sweden (Malmö and Umeå)
and the United Kingdom (Cambridge and Oxford). Parti-
cipants were recruited from the general population of their
respective countries, with the following exceptions: the
French cohort were teacher health insurance programme
members; the Italian and Spanish cohort included members
of blood donor associations and the general population; the
Utrecht and Florence cohorts contained participants from
mammographic screening programmes; the Oxford cohort
included a large proportion of vegetarians, vegans and low
meat eaters; ﬁnally, only women participated in the cohorts
of France, Norway, Utrecht and Naples. Additional details
of the design and methods used in the EPIC study has been
published elsewhere [17]. The study was approved by all
relevant ethical review boards, and all participants provided
consent for the retention of acquired data and follow-up for
incidence of cancer and death.
In the present study, we excluded participants with pre-
valent cancer at baseline (except non-melanoma skin can-
cer, n= 25,185), participants missing information on diet
(n= 6205) or smoking (n= 11,696) and participants within
the extreme percentiles of the ratio of energy intake to
estimated energy requirement (n= 9573) or body mass
index (BMI) (≤18.11 kg/m2, n= 4920; ≥38.54 kg/m2, n=
4932). Additionally, we excluded participants whose
recorded date of loss to follow-up or death was on the same
date as recruitment (n= 25), completion of lifestyle ques-
tionnaires (n= 402) or completion of the dietary ques-
tionnaires (n= 46,440). In total, there were 416,746
participants included in the present study.
Assessment of diet, lifestyle and anthropometry
At baseline, participants reported dietary intake using
country-speciﬁc validated questionnaires. In most centres, a
self-administered food frequency questionnaire (FFQ) was
used to assess intake over the past 12 months (88–266 food
items). In Denmark, Norway, Naples (Italy) and Umeå
(Sweden), semiquantitative FFQs were administered. A
combination of dietary methods (semiquantitative FFQ and
diet record) was adopted in Malmö (Sweden) and the
United Kingdom. In order to standardise the dietary infor-
mation received from all centres, 24-h dietary recall data
was taken in 5–12% of participants in each subcohort to
correct for over- or under-estimations between centres [18].
Usual intake of total iron was assessed by multiplying the
iron content per food source according to the EPIC Nutrient
Database with the individual mean daily intake of related
food sources. To obtain product-speciﬁc estimates of haem
iron intake, published data on percentages of haem iron to
total iron content in different animal products were applied
to total iron (65% for cooked beef, 39% for pork and 26%
for chicken or ﬁsh) and then summed to obtain individual's
total haem iron intake [19, 20]. Further details on metho-
dology have been published previously [21]. Non-haem
iron was calculated by subtracting haem iron estimates from
total dietary iron.
Non-dietary information was also collected on variables
related to dietary status, likely or potential risk factors for
cancer. A standardised set of questions was agreed between
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the original seven EPIC countries (France, Germany,
Greece, Italy, the Netherlands, Spain and United Kingdom),
which included those on education, health history, smoking
history (smoking status: current, former, never, number of
cigarettes currently smoked and duration of smoking),
alcohol consumption patterns, physical activity, hormone
replacement therapy use, contraception use and any expo-
sure to previous carcinogens [17]. Questionnaires from
centres that joined the study later (those in Denmark,
Sweden, Norway and Naples) were re-coded and standar-
dised to original EPIC questions. Anthropometric mea-
surements varied by centre: height, weight, and waist and
hip circumference were measured in all EPIC centres
excluding France, Oxford and Norway. In France and
Oxford, this information was obtained through either self-
reporting or on-site measurement. The Cambridge index of
physical activity was derived by combining occupational
activity level with recreational activity, as assessed by the
amount of time in hours per week during winter and sum-
mer spent cycling and in other physical exercises (e.g.
jogging, swimming) [22].
Blood was taken from 385,747 of EPIC participants,
most of which is stored and managed at the International
Agency for Research on Cancer (IARC) central biological
bank. Filled syringes were kept at 5–10 °C, protected from
light and transferred to a local laboratory for further pro-
cessing. Blood fractions (serum, citrate plasma, red cells
and buffy coat) were aliquoted into 0.5-mL straws that were
subsequently heat sealed and stored in liquid nitrogen tanks
at the IARC, Lyon, France, at −196 °C, except in Umeå,
Sweden, where samples were stored in 1.8-mL plastic tubes
in −80 °C freezers. All biochemical analyses, including
measurements of serum cotinine, were performed at Bevital
A/S (http://www.bevital.no), Bergen, Norway.
Cotinine nested case–control subset
The association between haem iron intake and lung cancer
was examined in an existing nested case–control data set for
which serum cotinine, a biomarker of tobacco exposure,
was available [23]. In brief, two control participants per
lung cancer case were chosen at random from appropriate
risk sets consisting of all cohort members alive and cancer
free (except non-melanoma skin cancer) at the time of
diagnosis of the index case. Matching criteria were country,
sex, date of blood collection ( ± 1 month, relaxed to ±
5 months for sets without available controls) and date of
birth ( ± 1 year, relaxed to ± 5 years for sets without avail-
able control participants). The nested case–control subset
for the present analysis included 800 cases and 1489
controls.
End point deﬁnition
In seven study countries (Denmark, Italy, the Netherlands,
Norway, Spain, Sweden and United Kingdom), information
on incident cancer cases was obtained through population
cancer registries. Health insurance records, cancer and
pathology registries and active follow-up of participants and
next of kin were used as available in the remaining three
countries (France, Germany and Greece). The last date of
follow-up varied by EPIC centre and ranged from June
2008 to December 2013.
Outcomes for the purposes of this analysis were ﬁrst
primary, incident lung cancer cases using the International
Classiﬁcation of Diseases for Oncology (ICD-O-2) site code
C34. Furthermore, we conducted analyses by histologic
subtypes of lung cancer according to the following ICD-O
morphology codes: squamous-cell cancer (codes 8070,
8071, 8072, 8073, 8075, 8083, 8094 and 8123), small cell
cancer (codes 8041, 8042, 8043, 8044, 8045 and 8246),
large-cell cancer (codes 8012, 8020 and 8021), adeno-
carcinoma (codes 8140, 8200, 8211, 8230, 8250, 8251,
8253, 8260, 8310, 8470, 8480, 8481, 8490 and 8550) and
‘unclassiﬁed’ (codes 8000, 8001, 8003, 8010, 8011, 8022,
8030, 8031, 8032, 8046, 8240, 8560, 8710, 8800, 8801,
8990, 9120, 9133 and 9699). Among the 416,746 indivi-
duals with a mean of 13.9 follow-up years, 3731 incident,
ﬁrst primary lung cancers were diagnosed and included in
this analysis; of these, 1335 were adenocarcinomas, 735
were squamous-cell carcinomas, 595 were small-cell can-
cers and 213 were large cell.
Statistics
Cox proportional hazards models were used to estimate
hazard ratios (HRs) and 95% CIs. P values reported are
two-sided and associations with P values < 0.05 were
considered statistically signiﬁcant. Age was used as the
underlying time metric for all Cox models. When con-
structing the models, time of entry into the study was par-
ticipants’ age at recruitment, and time of exit was the age at
which the ﬁrst lung cancer was recorded, the time of death,
loss to follow-up or censoring. Schoenfeld residuals were
used to test the proportional hazards assumption for all
variables in the model. Where variables violated this
assumption—as was the case with smoking status—strati-
ﬁcation was performed to adjust the model.
The dose–response relationship was examined by ﬁtting
Cox proportional hazards models with restricted cubic
splines for haem iron, non-haem iron and total iron as
continuous variables, adjusted for the covariates in model 2
(described below). Knots were placed at the 5th, 25th, 75th
and 95th percentiles of intake followed by corresponding
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likelihood ratio tests comparing the goodness-of-ﬁt of the
models with and without the spline terms [24, 25]. The
nutritional exposures of interest (haem iron, total iron and
non-haem iron) were entered into the models as continuous
variables per 1000 kcal per day, re-scaled into units of
approximately one standard deviation; as sex-speciﬁc
quintiles and as a trend variable (quintile sex-speciﬁc mid-
points assigned).
All Cox regression models were stratiﬁed by sex, centre,
age at recruitment (1-year groupings) and smoking status
(current, former or never). Adjustment for potential con-
founders was conducted in three steps. First, model 1 was
adjusted for total caloric intake, as per the multivariate
nutrient density method for energy adjustment. Second,
model 2 was adjusted additionally for socioeconomic and
lifestyle confounders identiﬁed from cancer-related meta-
analyses [26] and an earlier EPIC study: [27] BMI
(<18.5 kg/m2, 18.5–24.9 kg/m2, 25–29.9 kg/m2, >30 kg/m2);
education (none/primary school, technical/professional,
secondary, longer education or missing), height (cm),
physical activity (Cambridge index categories: inactive,
moderately inactive, moderately active, active or missing),
and total fat (g/1000 kcal). Third, model 3 was further
adjusted for time since quitting (years) and number of
cigarettes per day. Owing to a high proportion of missing
data (n= 47,555 for number cigarettes per day, 4787 for
time since quitting), multiple imputation was used for this
analysis (SAS PROC MI and MIANALYZE, number of
iterations= 20). The predictor variables for the multiple
imputation of time since quitting and number of cigarettes
per day were the primary dietary variables of interest (total
iron, haem iron and non-haem iron), all covariates listed for
model 2 above, plus sex, age and total person years of
follow-up (the latter was log-transformed).
The analyses above were repeated separately by smoking
status and by tumour histologic subtype. In addition, sex-
stratiﬁed results are presented in online supplementary
information table for comparison with the results from other
cohorts.
In analyses of the nested case–control subset with serum
cotinine available, conditional logistic regression analyses
(matched) were conducted to estimate odds ratios and 95%
CIs for lung cancer risk by iron intake on a continuous
scale. Adjustment for confounders was conducted in a
multi-step process in parallel to the analysis of the full EPIC
cohort, described above. As in the main analysis, multiple
imputation was used in the adjustment for time since quit-
ting smoking and number of cigarettes per day due to a high
proportion of missing data.
Sensitivity analyses included (i) restriction of the analysis
to those with ≥2 years of follow-up to reduce the potential
inﬂuence of undiagnosed prevalent cancer cases at baseline;
(ii) adjustment for alcohol, fruit, vegetables, vitamin C,
calcium and beta-carotene (related to non-haem iron
absorption); (iii) adjustment for central adiposity (waist cir-
cumference, waist to height ratio); and (iv) running model 3
from Table 2 as a complete case analysis rather than
imputing missing data. Lastly, tests for interaction between
haem iron, non-haem iron and total iron by dichotomised
intake of fruit, vegetables and vitamin C (based on median
intake in the cohort) were conducted using Wald test.
Analyses were performed using SAS version 9.3 (SAS
Institute, Inc., Cary, NC).
Results
Descriptive statistics and evaluation of linearity of
associations
Descriptive statistics of the cohort according to quintile of
haem intake are presented in Table 1. Those in the highest
quintile of haem intake had relatively higher BMI values,
were more likely to be current smokers and to report lower
levels of education and vitamin C intake than those in the
lower quintiles of intake (Table 1). The cubic spline ana-
lysis indicated that there was no evidence of non-linearity
for haem iron (P= 0.13), non-haem iron (P= 0.14) or total
iron (P= 0.089) (Supplementary Figures 1–3).
Cox regression analysis
The data from this study showed that higher intake of haem
iron was positively associated with the risk of lung cancer.
After adjusting for potential confounders, including details
of smoking behaviour (model 3), the risk of lung cancer was
16% higher in the highest quintile of haem intake compared
to the lowest, with a signiﬁcant test for trend across quin-
tiles (Table 2), and a modest but signiﬁcant association for
haem as a continuous variable (HR per 0.3 mg/1000 kcal
1.03, 95% CI 1.00–1.07). In contrast, there was a suggestive
inverse association non-haem iron intake and lung cancer
risk in EPIC. Prior to adjusting for time since quitting and
number of cigarettes per day, the risk of lung cancer was
signiﬁcantly lower in all quintiles of non-haem relative to
the lowest group, with a signiﬁcant trend across quintiles
and an inverse association when analysed as a continuous
variable (HR per 1.2 g/1000 kcal 0.92, 95% CI 0.88–0.96)
(Table 2). Adjustment for details of smoking history (model
3) attenuated the associations in each quintile of non-haem
iron, the trend test and for non-haem as a continuous vari-
able. For total iron, adjustment for details of smoking his-
tory also attenuated the formerly signiﬁcant trend across
quintiles and the analysis of continuous intake (HR per
1.3 g/1000 kcal 0.98, 95% CI 0.94–1.02). These results are
presented separately for men and women in Supplementary
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Table 1; however, there was no evidence of effect mod-
iﬁcation by sex in relation to haem iron (P= 0.11), non-
haem (P= 0.47) or total iron (P= 0.66).
Subgroup and sensitivity analyses
In the analysis by histological types, the effect sizes yielded
for adenocarcinoma in relation to haem, non-haem and total
iron intakes were broadly similar to those seen for all lung
cancers, although not statistically signiﬁcant in the fully
adjusted models (Table 3). In contrast, haem iron intake was
positively associated with the risk of small-cell lung cancer
(HR per 0.3 mg/1000 kcal 1.13, 95% CI 1.04–1.21) and
modestly associated with total iron intake (HR per 1.3 g/
1000 kcal 1.11, 95% CI 1.00–1.22) after adjustment for
details of smoking history (model 3, Table 3).
Stratiﬁcation by smoking status yielded results among
current smokers that were broadly similar to those detected
at group level (Table 4). For haem iron and non-haem iron,
there was no evidence of an interaction across smoking
groups and lung cancer risk. For total iron, there was a
borderline signiﬁcant interaction detected (P 0.05, Table 4);
among former smokers, an inverse association with lung
cancer risk was detected (HR per 1 SD 0.90, 95% CI 0.83 –
0.97).
Further adjustment for serum cotinine did not sub-
stantially modify the observed effect sizes (Table 5). For
non-haem iron, the corresponding adjustment for serum
cotinine modestly attenuated the results observed relative to
models without serum cotinine (HRs and 95% CI on a
continuous scale: 0.94 (0.81–1.09) and 0.90 (0.78–1.03),
respectively, Table 5). For total iron, the attenuation was
similar to that observed for non-haem iron (Table 5).
Additional sensitivity analyses yielded results that were
not materially different to those presented in Table 2: the
exclusion of the ﬁrst 2 years of follow-up, adjustment for
alcohol, fruits, vegetables, vitamin C, calcium and beta-
carotene or adjustment for central adiposity (waist cir-
cumference and waist to height ratio). Restricting the
adjustment for details of smoking history (Table 2, model 3)
to those with complete data on details of smoking history
yielded similar results to those obtained in the imputed
models (Supplementary Table 2). There was no evidence of
interactions between haem iron intake and fruit, vegetables
or vitamin C (P= 0.17, 0.29 and 0.60, respectively) and
lung cancer risk; similarly, the corresponding tests for
interaction were null for non-haem iron (P= 0.68, 0.72 and
0.43, respectively) and total iron (P= 0.40, 0.47 and 0.47,
respectively).
Discussion
The present analysis comprises the largest analysis of
dietary haem iron and lung cancer risk in a European
cohort, with a modest positive association between haem
iron intake and lung cancer risk detected. There was no
evidence of an interaction between smoking status, haem
iron intake and the risk of lung cancer, and adjustment for
serum cotinine had a minimal impact on the observed haem
iron–lung cancer association. The association between
Table 1 Baseline health, lifestyle and demographic characteristics
according to study-wide ﬁfths of haem iron intake (mg/1000 kcal) in
the EPIC study
Characteristic by haem
quintilea
Q1 Q2 Q3 Q4 Q5
No. of individuals 83,349 83,349 83,350 83,350 83,348
Haem iron
(mg/1000 kcal)
0.15 0.37 0.52 0.69 0.98
Age (years) 49.2 51.6 52.1 52.5 52.3
BMI (kg/m2) 23.5 24.7 25.0 25.3 25.6
Height (cm) 167 166 166 165 165
Smoking status (%)b
Never 55.6 49.7 48.0 48.3 49.7
Former 29.6 28.7 27.6 26.5 24.2
Current 14.8 21.7 24.4 25.2 26.1
Highest education level (%)b
None 1.9 4.6 5.1 5.5 6.3
Primary school 13.1 23.6 25.9 27.3 28.2
Technical/professional
school
22.4 25.3 25.5 24.2 20.3
Secondary school 19.0 19.4 19.4 19.9 21.2
Longer education 36.0 23.8 21.7 20.8 21.9
Physical activity (%)b
Inactive 19.1 19.4 19.3 20.3 22.4
Moderately inactive 33.1 31.6 31.7 32.5 34.0
Moderately active 26.5 28.7 28.4 27.2 25.3
Active 20.1 18.3 18.4 18.4 17.1
Alcohol (g/day) 4.79 4.79 5.67 6.39 6.00
Energy (kcal/day) 1927 1980 2022 2025 1934
Red meat (g/1000 kcal) 2.82 13.1 20.0 27.5 35.7
White meat (g/1000 kcal) 1.19 6.25 7.48 8.58 9.49
Processed meat
(g/1000 kcal)
3.84 13.1 15.0 15.5 18.1
Total iron
(mg/1000 kcal)
5.99 5.85 6.08 6.37 7.06
Non-haem iron
(mg/1000 kcal)
5.85 5.49 5.56 5.68 6.02
Vitamin C
(mg/1000 kcal)
64.2 56.0 54.8 54.7 55.5
Vegetables (g/1000 kcal) 109 95.2 91.9 91.4 92.0
Fruit (g/1000/kcal) 104.9 91.8 88.7 88.6 89.3
aValues are medians unless otherwise noted
bData does not sum to 100% due to missing data
1126 H. A. Ward et al.
haem iron and lung cancer appeared to be restricted to the
small-cell histologic subtype. In contrast, non-haem iron
was inversely associated with lung cancer risk, though the
attenuation after adjustment for details of smoking history
and after adjustment for serum cotinine in the nested
case–control subset suggest that this association may be due
to confounding.
The suggested positive association between haem iron
and lung cancer risk in EPIC is of a similar magnitude to
that detected in the largest study on the association to date,
the US NIH-AARP study, which included 6361 incident
cases of lung cancer [10]. In a comparably adjusted model,
effect sizes were slightly stronger in NIH-AARP than in
EPIC and were statistically signiﬁcant among both men and
Table 2 Hazard ratios (HRs) and 95% CIs for lung cancer risk by haem iron, non-haem and total iron intakes in the EPIC study
Q1 Q2 Q3 Q4 Q5 P for trend HR (95% CI) per ~1 SDa
Haem iron (n cases)b 437 682 807 875 930
Model 1 1.0 (ref.) 1.09 (0.96–1.24) 1.19 (1.05–1.35) 1.22 (1.07–1.39) 1.32 (1.16–1.50) <0.0001 1.07 (1.04–1.10)
Model 2 1.0 (ref.) 1.08 (0.95–1.22) 1.17 (1.03–1.33) 1.19 (1.04–1.35) 1.27 (1.12–1.45) 0.0001 1.06 (1.03–1.09)
Model 3 1.0 (ref.) 1.06 (0.93–1.20) 1.12 (0.98–1.27) 1.11 (0.98–1.27) 1.16 (1.02–1.32) 0.0349 1.03 (1.00–1.07)
Non-haem iron (n cases)b 1092 822 671 619 527
Model 1 1.0 (ref.) 0.83 (0.76–0.92) 0.76 (0.68–0.84) 0.78 (0.70–0.86) 0.75 (0.66–0.85) <0.0001 0.89 (0.85–0.92)
Model 2 1.0 (ref.) 0.86 (0.78–0.95) 0.80 (0.73–0.89) 0.84 (0.75–0.94) 0.82 (0.72–0.94) 0.0004 0.92 (0.88–0.96)
Model 3 1.0 (ref.) 0.93 (0.85–1.03) 0.90 (0.81–1.00) 0.93 (0.83–1.04) 0.90 (0.79–1.02) 0.068 0.96 (0.92–1.00)
Total iron (n cases)b 982 815 724 619 591
Model 1 1.0 (ref.) 0.87 (0.79–0.96) 0.82 (0.74–0.91) 0.78 (0.70–0.87) 0.83 (0.73–0.94) 0.0001 0.93 (0.89–0.96)
Model 2 1.0 (ref.) 0.90 (0.81–0.99) 0.86 (0.78–0.96) 0.84 (0.75–0.94) 0.90 (0.79–1.02) 0.018 0.95 (0.92–0.99)
Model 3 1.0 (ref.) 0.96 (0.87–1.06) 0.94 (0.85–1.05) 0.92 (0.82–1.03) 0.95 (0.84–1.07) 0.20 0.98 (0.94–1.02)
Model 1: adjusted for total energy; stratiﬁed by age (1 year), centre and smoking status (current, former, never)
Model 2: additionally adjusted for BMI (<18.5 kg/m2, 18.5–24.9 kg/m2, 25–29.9 kg/m2, >30 kg/m2); education (none/primary school, technical/
professional, secondary, longer education or missing); height (cm); physical activity (Cambridge index categories) and fat (g/1000 kcal)
Model 3: additionally adjusted for time since quitting smoking (years) and number of cigarettes per day
aApproximately 1 SD= 0.3 for haem iron (mg/1000 kcal), 1.3 for total iron (g/1000 kcal) and 1.2 for non-haem iron (g/1000 kcal)
bmg/1000 kcal
Table 3 Hazard ratios (HRs)
CIs for lung cancer by baseline
haem iron, non-haem and total
iron intakes, by tumour
histological typea, in the EPIC
study
Squamous cell Small cell Adenocarcinoma Large cell
HR, 95% CI per 1 SDb HR, 95% CI per 1 SDb HR, 95% CI per 1 SDb HR, 95% CI per 1 SDb
n= 735 n= 595 n= 1335 n= 213
Haem iron (mg/1000 kcal)
Model 1 1.04 (0.97–1.12) 1.18 (1.10–1.26) 1.06 (1.01–1.12) 1.01 (0.90–1.13)
Model 2 1.03 (0.96–1.11) 1.15 (1.07–1.24) 1.06 (1.01–1.12) 1.01 (0.89–1.13)
Model 3 0.99 (0.92–1.07) 1.13 (1.04–1.21) 1.04 (0.99–1.10) 0.99 (0.87–1.12)
Non-haem iron (mg/1000 kcal)
Model 1 0.87 (0.79–0.96) 0.95 (0.86–1.06) 0.91 (0.84–0.97) 0.88 (0.75–1.03)
Model 2 0.90 (0.82–1.00) 1.02 (0.91–1.13) 0.93 (0.87–1.00) 0.89 (0.75–1.05)
Model 3 0.95 (0.86–1.04) 1.07 (0.96–1.19) 0.97 (0.90–1.04) 0.94 (0.80–1.10)
Total iron (mg/1000 kcal)
Model 1 0.90(0.82–0.99) 1.03 (0.93–1.14) 0.94 (0.88–1.01) 0.90 (0.77–1.05)
Model 2 0.93 (0.85–1.02) 1.07 (0.97–1.19) 0.97 (0.90–1.04) 0.91 (0.78–1.06)
Model 3 0.95 (0.87–1.04) 1.11 (1.00–1.22) 0.99 (0.92–1.06) 0.95 (0.81–1.10)
Model 1: adjusted for total energy; stratiﬁed by age (1 year), centre and smoking status (current, former,
never)
Model 2: additionally adjusted for BMI (<18.5 kg/m2, 18.5–24.9 kg/m2, 25–29.9 kg/m2, >30 kg/m2);
education (none/primary school, technical/professional, secondary, longer education or missing); height
(cm); physical activity (Cambridge index categories) and fat (g/1000 kcal)
Model 3: additionally adjusted for time since quitting smoking (years) and number of cigarettes per day
aThere were 452 unclassiﬁed tumours in the present analysis
bApproximately 1 SD= 0.3 for haem iron (mg/1000 kcal), 1.3 for total iron (g/1000 kcal) and 1.2 for non-
haem iron (g/1000 kcal)
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women. In addition to greater statistical power, the esti-
mates of haem iron in NIH-AARP were calculated from a
database of haem in speciﬁc food items rather than broader
food groups as was the case in EPIC; this may have also
contributed to the stronger effects seen in the former study.
Our observation of no material differences for the associa-
tion between haem iron and lung cancer risk by smoking
status were consistent with the NIH-AARP conclusion of no
difference among current, former or never smokers and after
sensitivity analyses controlling for smoking status, smoking
intensity and time since quitting. Analysis of another US
cohort, the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial, used the same haem content database as
NIH-AARP but reported no association between haem and
lung cancer; however, that was a notably smaller cohort (n
= 782 lung cancer cases) [12]. Other smaller studies found
no association between haem intake and lung cancer risk
overall [9, 10] but one detected a positive association
among users of vitamin C supplements.
There has been very limited study of dietary iron and
non-haem iron in relation to lung cancer in cohort studies.
In the Rotterdam study, no association between non-haem
iron and risk of lung cancer was reported, but as noted
previously that analysis included only a small number of
lung cancer cases [10]. In the NIH-AARP study, total iron
intake was inversely associated with lung cancer risk, with
signiﬁcantly lower risks in the highest versus lowest quintile
(HR 0.87, 95% CI 0.79–0.97) and an inverse trend across
quintiles [28]. In the present analysis, total iron was
inversely associated with lung cancer risk among former
smokers only. The covariates included in the analysis of the
NIH-AARP cohort were similar to those used in the present
analysis, including details of smoking history [28].
Non-haem comprises the majority of dietary iron,
therefore the relative consistency of results for total iron and
non-haem iron in the present result are unsurprising. An
apparent protective effect of iron in relation to lung cancer
is somewhat unexpected in the context of the oxidative
potential of iron, including the Fenton reaction, a process
that causes the conversion of hydrogen peroxide and
superoxide to free radicals [29]. The imbalance in redox
reactions brought about by iron excess may lead to pre-
mature cell aging and death [30]. We are unaware of any
proposed biological pathways for a protective effect of iron
or non-haem iron on cancer risk; however, haem iron is
absorbed two to three times more readily than non-haem
Table 4 Hazard ratios (HRs) for
lung cancer by baseline haem
iron, non-haem and total iron
intakes, by smoking status, in
the EPIC study
Never smoker Former smoker Current smoker
HR, 95% CI per 1 SDa HR, 95% CI per 1 SDa HR, 95% CI per 1 SDa
n= 335 n= 889 n= 2507
Haem iron (mg/1000 kcal)
Model 1 0.96 (0.86–1.08) 1.07 (1.00–1.14) 1.08 (1.04–1.12)
Model 2 0.96 (0.86–1.07) 1.06 (0.99–1.14) 1.07 (1.03–1.11)
Model 3 0.96 (0.86–1.07) 0.99 (0.93–1.06) 1.04 (1.01–1.08)
P for interactionb 0.428
Non-haem iron (mg/1000kcal)
Model 1 1.04 (0.92–1.18) 0.83 (0.77–0.91) 0.89 (0.84–0.94)
Model 2 1.07 (0.94–1.21) 0.86 (0.79–0.94) 0.92 (0.88–0.97)
Model 3 1.07 (0.94–1.21) 0.89 (0.83–0.96) 0.96 (0.92–1.01)
P for interactionb 0.065
Total iron (mg/1000 kcal)
Model 1 1.03 (0.91–1.16) 0.87 (0.80–0.94) 0.93 (0.89 – 0.98)
Model 2 1.05 (0.93–1.18) 0.89 (0.82–0.97) 0.96 (0.91–1.01)
Model 3 1.05 (0.93–1.18) 0.90 (0.83–0.97) 0.99 (0.94–1.03)
P for interactionb 0.048
Model 1: adjusted for total energy; stratiﬁed by sex, age (1 year), centre and smoking status (current, former,
never)
Model 2: additionally adjusted for BMI (<18.5 kg/m2, 18.5–24.9 kg/m2, 25–29.9 kg/m2, >30 kg/m2);
education (none/primary school, technical/professional, secondary, longer education or missing); height
(cm); physical activity (Cambridge index categories) and fat (g/1000 kcal)
Model 3: additionally adjusted for time since quitting smoking (years) and number of cigarettes per day
aApproximately 1 SD= 0.3 for haem iron (mg/1000 kcal), 1.3 for total iron (g/1000 kcal) and 1.2 for non-
haem iron (g/1000 kcal)
bTest for interaction conducted using Model 3
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iron and also increases absorption of the latter when eaten
together, thus haem iron poses a much greater risk of
overload than non-haem iron [30]. More importantly, dif-
ferences in dietary sources of haem and non-haem iron may
have contributed to the divergent associations detected in
the present analysis: sources of haem iron include red
meats, poultry and ﬁsh, whereas non-haem iron is found in
many plant products and in dairy [30], as well as iron-
fortiﬁed foods such as cereals and grains [30]. Therefore,
the inverse association detected for non-haem iron may
reﬂect other anticarcinogenic properties of food sources
high in non-haem iron (e.g. antioxidants in fruits and
vegetables, a food group associated with lower risk of lung
cancer) [31] rather than a speciﬁc biological pathway for
non-haem iron. Sensitivity analyses included the addition of
fruit and vegetable intake to the models, which did not
affect our ﬁndings but the possibility of uncontrolled con-
founding cannot be ruled out.
In analyses by histologic subtype, the association
between haem iron intake and lung cancer risk was only
signiﬁcant for small-cell carcinomas, and the effect size was
larger than that estimated for the other types of lung cancer
under study. The underlying causes of these differences are
unclear. Small-cell carcinoma is a comparatively fast-
growing form of cancer that is highly metastatic and is
rare in non-smokers. It is possible that the associations
detected between haem iron, total iron and small-cell car-
cinoma in the present study reﬂects uncontrolled con-
founding due to smoking; however, such confounding
would also have been expected to yield associations for
squamous-cell carcinoma, as both histological types are
strongly related to tobacco exposure [32].
Strengths of the present study include a large sample
size, long follow-up time and detailed information collected
on diet and a wide range of potentially confounding cov-
ariates, including tobacco exposure. We endeavoured to
control for confounding by smoking through adjustment for
details of smoking history, examining associations sepa-
rately by smoking status and adjusting for serum cotinine
values in a nested subset of participants. However, it is
impossible to fully exclude the possibility of confounding
by smoking or other factors (such as carcinogenic advanced
glycation end products, yielded when meat is cooked at
high temperatures [33]), particularly in the context of the
modest effect size detected. Never smokers comprised only
9% of lung cancer cases in the present analysis; therefore,
there was limited power to examine this subgroup.
Adjustment for serum cotinine measurements would have
provided some control for second-hand smoke exposure at
baseline [34], although information on longer-term expo-
sure would have been valuable. Similarly, detailed infor-
mation on vitamin and mineral supplement use may have
been informative, both for examining supplementary iron
intake and further exploring the interaction between haem
and supplementary vitamin C previously reported [9]. In
EPIC, standardised questions on supplement use were only
included in a calibration substudy of participants (n=
36,994); [35] otherwise, study centres varied in the nature
of supplement data collected and harmonised variables are
not available. It is possible that the use of a more detailed
database of haem content, rather than applying a constant
value per meat type, could have yielded different results.
Lastly, in 2015 the World Health Organisation issued an
update to their guidelines for the classiﬁcation of lung
tumours, which included notable changes to the classiﬁca-
tion of large-cell carcinomas [36]; the present analysis by
histological subtype in EPIC would not have reﬂected the
current guidelines and therefore may include some mis-
classiﬁcation, particularly for large-cell carcinomas.
Table 5 Odds ratios for lung cancer in relation to haem iron, non-
haem and total iron intakes among a case–control subset of the EPIC
study, with adjustment for serum cotinine
800 cases, 1489 controls,
OR per 1 SDa (95% CI)
Haem iron (mg/1000 kcal)
Model 1 1.08 (0.99–1.18)
Model 2 1.06 (0.96–1.16)
Model 3 1.02 (0.92–1.14)
Model 4 1.01 (0.90–1.13)
Model 5 1.01 (0.89–1.14)
Non-haem iron (mg/1000 kcal)
Model 1 0.81 (0.72–0.90)
Model 2 0.84 (0.74–0.95)
Model 3 0.86 (0.75–0.99)
Model 4 0.90 (0.78–1.03)
Model 5 0.94 (0.81–1.09)
Total iron (mg/1000 kcal)
Model 1 0.85 (0.76–0.95)
Model 2 0.88 (0.78–0.99)
Model 3 0.89 (0.78–1.01)
Model 4 0.91 (0.80–1.05)
Model 5 0.95 (0.82–1.09)
Model 1: adjusted for age, total energy (kcal)
Model 2: additionally adjusted for BMI (<18.5 kg/m2, 18.5–24.9 kg/
m2, 25–29.9 kg/m2, >30 kg/m2); education (none/primary school,
technical/professional, secondary, longer education or missing); height
(cm); physical activity (Cambridge index categories) and fat (g/
1000 kcal)
Model 3: additionally adjusted for smoking status (current, former,
never)
Model 4: additionally adjusted for time since quitting and number of
cigarettes per day (imputed)
Model 5: additionally adjusted for serum cotinine
aApproximately 1 SD= 0.3 for haem iron (mg/1000 kcal), 1.3 for total
iron (g/1000 kcal) and 1.2 for non-haem iron (g/1000 kcal)
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Implications and future research
The results from EPIC are suggestive of a moderately
positive association between haem intake and lung cancer;
this observation is consistent with evidence from the largest
study to date, conducted among US adults. Further study of
populations within Europe and internationally will help
determine the consistency of this association. The possible
protective effect of non-haem iron in the current study has
not been reported previously and warrants further study to
determine the strength and reliability of this association and,
if found to be robust, to understand the underlying
mechanisms. Continued research on dietary risk factors for
lung cancer may yield insight that informs preventive
measures complementary to anti-tobacco strategies.
Data sharing
For information on how to submit an application for gaining
access to EPIC data and/or biospecimens, please follow the
instructions at http://epic.iarc.fr/access/index.php
Acknowledgements The coordination of EPIC is ﬁnancially supported
by the European Commission (DG-SANCO) and the International
Agency for Research on Cancer. The national cohorts are supported by
Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut
Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut
National de la Santé et de la Recherche Médicale (INSERM) (France);
German Cancer Aid, German Cancer Research Centre (DKFZ), Fed-
eral Ministry of Education and Research (BMBF), Deutsche Kreb-
shilfe, Deutsches Krebsforschungszentrum and Federal Ministry of
Education and Research (Germany); the Hellenic Health Foundation
(Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy
and National Research Council (Italy); Dutch Ministry of Public
Health, Welfare and Sports (VWS), Netherlands Cancer Registry
(NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON
(Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF),
Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and
Nordforsk, Nordic Centre of Excellence programme on Food, Nutri-
tion and Health (Norway); Health Research Fund (FIS), PI13/00061 to
Granada, PI13/01162 to EPIC-Murcia, Regional Governments of
Andalucía, Asturias, Basque Country, Murcia ((no. 6236) and Navarra,
ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swed-
ish Research Council and County Councils of Skåne and Västerbotten
(Sweden); Cancer Research UK (14136 to K.T. Khaw, N.J. Wareham;
C570/A16491 to RCT and C8221/A19170 to T. Key (EPIC-Oxford),
Medical Research Council (1000143 to K.T. Khaw, N.J. Wareham,
MR/M012190/1 to T. Key (EPIC-Oxford)) (United Kingdom).
Author Contributions AJC originated the idea. AJC was responsible
for the study design and data management. HW was responsible for
the statistical analysis. AJC, HW and JW drafted the ﬁrst version of the
manuscript, contributed to interpretation of results and revised the
manuscript critically for important intellectual content. All listed EPIC
co-authors contributed data and reviewed the ﬁnal manuscript.
Compliance with ethical standards
Conﬂict of interest The authors declare that they no conﬂict of
interest.
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eses S, Mathers C,
et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality
worldwide: IARC cancer base no. 11 [Internet]. Lyon, France:
International Agency for Research on Cancer; 2013. http://globoca
n.iarc.fr.
2. Danaei G, Vander HS, Lopez AD, Murray CJ, Ezzati M. Causes
of cancer in the world: comparative risk assessment of nine
behavioural and environmental risk factors. Lancet.
2005;366:1784–93.
3. Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk
factors for lung cancer worldwide. Eur Respir J.
2016;48:889–902.
4. Yang WS, Wong MY, Vogtmann E, Tang RQ, Xie L, Yang YS,
et al. Meat consumption and risk of lung cancer: evidence from
observational studies. Ann Oncol. 2012;23:3163–70.
5. Heath A-LM, Fairweather-Tait SJ. Clinical implications of chan-
ges in the modern diet: iron intake, absorption and status. Best
Pract Res Clin Haematol. 2002;15:225–41.
6. Cross AJ, Pollock J, Bingham SA. Haem, not protein or inorganic
iron, is responsible for endogenous intestinal N-nitrosation arising
from red meat. Cancer Res. 2003;63:2358–60.
7. Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk--a
systematic review and meta-analysis of the epidemiological evi-
dence. Cancer Epidemiol Biomark Prev. 2014;23:12–31.
8. Hooda J, Cadinu D, Alam MM, Shah A, Cao TM, Sullivan LA,
et al. Enhanced heme function and mitochondrial respiration
promote the progression of lung cancer cells. PLoS ONE. 2013;8:
e63402.
9. Lee D-H, Jacobs David RJ. Interaction among heme iron, zinc,
and supplemental vitamin C intake on the risk of lung cancer:
Iowa Women’s Health Study. Nutr Cancer. 2005;52:130–7.
10. Muka T, Kraja B, Ruiter R, Lahousse L, de Keyser CE, Hofman
A, et al. Dietary mineral intake and lung cancer risk: the Rotter-
dam Study. Eur J Nutr. 2017;56:1637–46.
11. Tasevska N, Sinha R, Kipnis V, Subar AF, Leitzmann MF, Hol-
lenbeck AR, et al. A prospective study of meat, cooking methods,
meat mutagens, heme iron, and lung cancer risks. Am J Clin Nutr.
2009;89:1884–94.
12. Tasevska N, Cross AJ, Dodd KW, Ziegler RG, Caporaso NE,
Sinha R. No effect of meat, meat cooking preferences, meat
mutagens or heme iron on lung cancer risk in the prostate, lung,
colorectal and ovarian cancer screening trial. Int J Cancer.
2011;128:402.
13. Zhou W, Park S, Liu G, Miller D, Wang L, Pothier L, et al.
Dietary iron, zinc, and calcium and the risk of lung cancer. Epi-
demiology. 2005;16:772–9.
14. Bottoni A, Cannella C, Del VB. Lifestyle and dietary differences
in smokers and non-smokers from an Italian employee population.
Public Health. 1997;111:161–4.
15. Pan A, Sun Q, Bernstein AM, Schulze MB, Manson JE, Stampfer
MJ, et al. Red meat consumption and mortality: results from 2
prospective cohort studies. Arch Intern Med. 2012;172:555–63.
16. Sinha R, Cross AJ, Graubard BI, Leitzmann MF, Schatzkin A.
Meat intake and mortality: a prospective study of over half a
million people. Arch Intern Med. 2009;169:562–71.
17. Riboli E, Hunt K, Slimani N, Ferrari P, Norat T, Fahey M, et al.
European Prospective Investigation into Cancer and Nutrition
(EPIC): study populations and data collection. Public Health Nutr.
2002;5:1113–24.
18. Slimani N, Deharveng G, Charrondiere RU, Van Kappel AL,
Ocke MC, Welch A, et al. Structure of the standardized compu-
terized 24-h diet recall interview used as reference method in the
22 centers participating in the EPIC project. European Prospective
1130 H. A. Ward et al.
Investigation into Cancer and Nutrition. Comput Prog Biomed.
1999;58:251–66.
19. CE C, Clark E. Evaluation of methods used in meat iron analysis
and iron content of raw and cooked meats. J Agric Food Chem.
1995;43:1824–7.
20. Kongkachuichai R. Heme and nonheme iron content in animal
products commonly consumed in Thailand. J Food Compos Anal.
2002;15:389–98.
21. Jakszyn P, Agudo A, Lujan-Barroso L, Bueno-de-Mesquita HB,
Jenab M, Navarro C, et al. Dietary intake of heme iron and risk of
gastric cancer in the European prospective investigation into
cancer and nutrition study. Int J Cancer. 2012;130:2654–63.
22. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hen-
nings S, et al. Validity and repeatability of a simple index derived
from the short physical activity questionnaire used in the Eur-
opean Prospective Investigation into Cancer and Nutrition (EPIC)
study. Public Health Nutr. 2003;6:407–13.
23. Johansson M, Relton C, Ueland PM, Vollset SE, Midttun O,
Nygard O, et al. Serum B vitamin levels and risk of lung cancer.
JAMA. 2010;303:2377–85.
24. Harrell FE Jr., Lee KL, Pollock BG. Regression models in clinical
studies: determining relationships between predictors and
response. J Natl Cancer Inst. 1988;80:1198–202.
25. Heinzl H, Kaider A. Gaining more ﬂexibility in Cox proportional
hazards regression models with cubic spline functions. Comput
Prog Biomed. 1997;54:201–8.
26. American Institute for Cancer Research/World Cancer Research
Fund. Food, nutrition, physical activity, and the prevention of
cancer: a global perspective. Washington DC: AIRC; 2007.
27. Dewi NU, Boshuizen HC, Johansson M, Vineis P, Kampman E,
Steffen A, et al. Anthropometry and the risk of lung cancer in
EPIC. Am J Epidemiol. 2016;184:129–39.
28. Mahabir S, Forman MR, Dong YQ, Park Y, Hollenbeck A,
Schatzkin A. Mineral intake and lung cancer risk in the NIH-
American Association of Retired Persons Diet and Health Study.
Cancer Epidemiol Biomark Prev. 2010;19:1976–83.
29. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic
metal ions in human disease: an overview. In: Packer EL, editor.
Oxygen radicals in biological systems part B: oxygen radicals and
antioxidants. New York: Academic Press; 1990. p. 1–85.
30. Yip R, Dallman PR. Iron. In: Ziegler EE, Filer LJ, editors. Present
knowledge in nutrition. Washington D.C.: International Life Sci-
ences Institute; 1996. p. 277–292.
31. Vieira AR, Abar L, Vingeliene S, Chan DS, Aune D, Navarro-
Rosenblatt D, et al. Fruits, vegetables and lung cancer risk: a
systematic review and meta-analysis. Ann Oncol. 2016;27:81–96.
32. Lee PN, Forey BA, Coombs KJ. Systematic review with meta-
analysis of the epidemiological evidence in the 1900s relating
smoking to lung cancer. BMC Cancer. 2012;12:385.
33. Turner DP. Advanced glycation end-products: a biological con-
sequence of lifestyle contributing to cancer disparity. Cancer Res.
2015;75:1925–9.
34. Lindsay RP, Tsoh JY, Sung HY, Max W. Secondhand smoke
exposure and serum cotinine levels among current smokers in the
USA. Tob Control. 2016;25:224–31.
35. Slimani N, Kaaks R, Ferrari P, Casagrande C, Clavel-Chapelon F,
Lotze G, et al. European Prospective Investigation into Cancer and
Nutrition (EPIC) calibration study: rationale, design and popula-
tion characteristics. Public Health Nutr. 2002;5:1125–45.
36. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH,
Beasley MB, et al. The 2015 World Health Organization Classi-
ﬁcation of Lung Tumors: impact of genetic, clinical and radiologic
advances since the 2004 classiﬁcation. J Thorac Oncol.
2015;10:1243–60.
Afﬁliations
Heather A. Ward1 ● Julia Whitman1 ● David C. Muller1 ● Mattias Johansson2 ● Paula Jakszyn3 ●
Elisabete Weiderpass 4,5,6,7 ● Domenico Palli8 ● Anouar Fanidi2 ● Roel Vermeulen9 ● Anne Tjønneland10 ●
Louise Hansen10 ● Christina C. Dahm11 ● Kim Overvad11,12 ● Gianluca Severi13,14 ● Marie-Christine Boutron-Ruault14 ●
Aurélie Affret14 ● Rudolf Kaaks15 ● Renee Fortner15 ● Heiner Boeing16 ● Antonia Trichopoulou17,18 ●
Carlo La Vecchia17,19 ● Anastasia Kotanidou17,20 ● Franco Berrino21 ● Vittorio Krogh21 ● Rosario Tumino22 ●
Fulvio Ricceri23,24 ● Salvatore Panico25 ● H. Bas Bueno-de-Mesquita1,26 ● Petra H. Peeters1,27 ●
Therese Haugdahl Nøst4 ● Torkjel M. Sandanger4 ● Jose Ramón Quirós28 ● Antonio Agudo29 ●
Miguel Rodríguez-Barranco30,31 ● Nerea Larrañaga31,32 ● Jose Maria Huerta31,33 ● Eva Ardanaz34,32,33,34,35,31 ●
Isabel Drake36 ● Hans Brunnström37,38 ● Mikael Johansson39 ● Kjell Grankvist 40 ● Ruth C. Travis41 ● Heinz Freisling2 ●
Magdalena Stepien2 ● Melissa A. Merritt1 ● Elio Riboli1 ● Amanda J. Cross1
1 School of Public Health, Imperial College London, London, UK
2 International Agency for Research on Cancer, Lyon, France
3 Unit of Nutrition, Environment and Cancer, Catalan Institute of
Oncology, Barcelona, Spain
4 Department of Community Medicine, Faculty of Health Sciences,
University of Tromsø, The Arctic University of Norway,
Tromsø, Norway
5 Department of Research, Cancer Registry of Norway, Institute of
Population-based Cancer Research, Oslo, Norway
6 Department of Medical Epidemiology and Biostatistics,
Karolinska Institutet, Stockholm, Sweden
7 Genetic Epidemiology Group, Folkhälsan Research Center and
Faculty of Medicine, University of Helsinki, Helsinki, Finland
8 Cancer Risk Factors and Life-Style Epidemiology Unit, Institute
for Cancer Research, Prevention and Clinical Network,
Florence, Italy
9 Division of Environmental Epidemiology, Institute for Risk
Assessment Sciences, Utrecht University, Utrecht, The
Netherlands
10 Danish Cancer Society Research Centre, Copenhagen, Denmark
11 Section for Epidemiology, Department of Public Health, Aarhus
University, Aarhus, Denmark
Haem iron intake and risk of lung cancer in the European Prospective Investigation into Cancer and. . . 1131
12 Department of Cardiology, Aalborg University Hospital,
Aalborg, Denmark
13 Human Genetics Foundation, Torino, Italy
14 CESP Inserm, Facultés de Medicine Université Paris-Sud, UVSQ,
Université Paris-Saclay, Gustave Roussy, Villejuif, France
15 Division of Cancer Epidemiology, German Cancer Research
Centre, Heidelberg, Germany
16 Department of Epidemiology, German Institute of Human
Nutrition, Potsdam-Rehbrücke, Germany
17 Hellenic Health Foundation, Athens, Greece
18 WHO Collaborating Centre for Nutrition and Health, Unit of
Nutritional Epidemiology and Nutrition in Public Health,
Department of Hygiene, Epidemiology and Medical Statistics,
School of Medicine, National and Kapodistrian University of
Athens, Athens, Greece
19 Department of Clinical Sciences and Community Health,
Università degli Studi di Milano, Milan, Italy
20 1st Department of Critical Care Medicine & Pulmonary Services,
University of Athens Medical School, Evangelismos Hospital,
Athens, Greece
21 Fondazione IRCCS National Cancer Institute, Milan, Italy
22 Cancer Registry and Histopathology Unit, “Civic - M.P.Arezzo”
Hospital, ASP Ragusa, Italy
23 Department of Clinical and Biological Sciences, University of
Turin, Orbassano, Italy
24 Unit of Epidemiology, Regional Health Service, ASL TO3
Grugliasco, Italy
25 Department of Clinical Medicine and Surgery, Federico II
University, Naples, Italy
26 Department for Determinants of Chronic Diseases, National
Institute for Public Health and the Environment, Bilthoven, The
Netherlands
27 Department of Epidemiology, Julius Centre for Health Sciences
and Primary Care, University Medical Centre Utrecht,
Utrecht, The Netherlands
28 Public Health Directorate, Asturias, Spain
29 Unit of Nutrition and Cancer, Cancer Epidemiology Research
Program, Catalan Institute of Oncology-IDIBELL. L’Hospitalet de
Llobregat, Barcelona, Spain
30 Escuela Andaluza de Salud Pública. Instituto de Investigación
Biosanitaria ibs.GRANADA, Hospitales Universitarios de
Granada/Universidad de Granada, Granada, Spain
31 CIBER Epidemiology and Public Health CIBERESP,
Madrid, Spain
32 Public Health Division and BioDonostia Research Institute,
San Sebastian, Spain
33 Department of Epidemiology, Murcia Regional Health Council,
IMIB-Arrixaca, Murcia, Spain
34 Public Health Institute, Pamplona, Spain
35 IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
36 Department of Clinical Sciences in Malmö, Lund University,
Malmö, Sweden
37 Department of Clinical Sciences Lund, Division of Oncology and
Pathology, Lund University, Malmö, Sweden
38 Laboratory Medicine, Department of Pathology, Lund University,
Malmö, Sweden
39 Department of Radiation Sciences, Oncology, Umeå University,
Umeå, Sweden
40 Department of Medical Biosciences, Clinical Chemistry, Umeå
University, Umeå, Sweden
41 Cancer Epidemiology Unit, Nufﬁeld Department of Population
Health University of Oxford, Oxford, UK
1132 H. A. Ward et al.
